Anebulo Pharmaceuticals Inc lost $0.25 per diluted share in fiscal year 2025. This represents an increase of 21.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.19 per diluted share. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters Anebulo Pharmaceuticals Inc has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.25
YoY+21.9%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
ANEB EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Anebulo Pharmaceuticals Inc's diluted earnings per share in fiscal year 2025?
Anebulo Pharmaceuticals Inc lost $0.25 per diluted share in fiscal year 2025.
How fast is Anebulo Pharmaceuticals Inc's diluted earnings per share growing?
Anebulo Pharmaceuticals Inc (ANEB) diluted earnings per share rose by 21.9% year over year, from -$0.32 to -$0.25 in fiscal year 2025.
What is Anebulo Pharmaceuticals Inc's diluted earnings per share over the last twelve months?
Anebulo Pharmaceuticals Inc (ANEB) reported a loss of $0.19 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Anebulo Pharmaceuticals Inc's diluted earnings per share in the most recent quarter?
Anebulo Pharmaceuticals Inc (ANEB) reported -$0.05 in diluted earnings per share in Q2 2026. This represents an increase of 44.4% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Anebulo Pharmaceuticals Inc (ANEB) reported on that line in every period on record.
